Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer

September 8, 2021 at 7:00 AM EDT

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- **Fulcrum Therapeutics, Inc.** (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Mel Hayes as Chief Commercial Officer, effective September 7, 2021. Mr. Hayes will be responsible for delivering an integrated global strategy that fully maximizes the potential of Fulcrum's transformative therapies.

"We are very excited to welcome Mel to Fulcrum as we plan for important milestones with our development programs and FulcrumSeek™," said Bryan Stuart, president and chief executive officer. "Mel brings broad experience in building commercial organizations and launching products in markets around the world. His expertise positions Fulcrum well to build the commercial capabilities required to deliver transformative therapies that treat the root cause of genetically defined rare diseases."

"With Fulcrum's recent progress with losmapimod and FTX-6058, the company is ideally positioned to transition from a research and development-stage organization to a commercial-stage organization," said Mr. Hayes. "I look forward to working with the experienced leadership team at Fulcrum, leveraging my extensive knowledge of commercialization strategies for therapies to treat rare diseases. I'm excited about the great work already in motion as we aim to bring new and innovative treatments to patients around the world."

Mr. Hayes is an industry leader with more than 25 years of Global and U.S. experience in all areas of product commercialization including marketing, sales, new product planning, pricing and reimbursement, advocacy and patient engagement. Prior to Fulcrum, Mr. Hayes most recently served as Global Head Commercial, Vice President, Rare Blood Disorders at Sanofi-Genzyme where he led the global commercial organization for hemophilia and complement assets. He also served as U.S. Vice President Hemophilia and Global Head, Hematology Rare Blood Disorders at Bioverativ (acquired by Sanofi-Genzyme). Prior to Bioverativ, he served as Global Vice President, Head of Global Marketing and Launch Excellence at Shire and at Baxalta (acquired by Shire) as Global Vice President Hemophilia. Prior to Baxalta, Mr. Hayes spent 10 years and nine years at Bayer and Bristol Myers Squibb respectively in progressive commercial leadership roles where he was responsible for launching products in Diabetes, Cardiovascular Disease, Neurology, Rheumatology, Multiple Sclerosis and Parkinson's Disease.

Mr. Hayes earned dual bachelor's degrees in Business and Communications from Southern Methodist University and an MBA from Columbia University.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia, into Phase 1 clinical development. Please visit www.fulcrumtx.com.

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Company's product candidates, the potential advantages and therapeutic potential of Fulcrum's product candidates and the Company's ability to transition from a research and development-stage organization to a commercial organization. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with Fulcrum's ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in clinical trials; initiate and enroll clinical trials on the timeline expected or at all; correctly estimate the potential patient population and/or market for the Company's product candidates; replicate in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials of losmapimod, FTX-6058 and its other product candidates; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section, as well as discussions of potential risks, uncertainties and other important factors, in the Company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Contact:

Investors:
Christi Waarich
Director, Investor Relations and
Corporate Communications
617-651-8664
cwaarich@fulcrumtx.com

Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
212-362-1200

Media:
Kaitlin Gallagher
Berry & Company Public Relations
kgallagher@berrypr.com
212-253-8881